Xenon Pharmaceuticals (XENE) Total Current Liabilities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Total Current Liabilities data on file, last reported at $39.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $39.8 million, up 24.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.8 million (up 24.31% YoY), and the FY2025 annual result was $41.8 million, up 17.43% from the prior year.
• Total Current Liabilities declined to $39.8 million in Q1 2026 per XENE's latest filing, from $41.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $41.8 million in Q4 2025 and troughed at $8.0 million in Q1 2022.
• A 5-year average of $27.4 million and a median of $28.2 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities sank 30.54% in 2022, then soared 181.77% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $22.7 million in 2022, then climbed by 20.13% to $27.3 million in 2023, then soared by 30.5% to $35.6 million in 2024, then advanced by 17.43% to $41.8 million in 2025, then declined by 4.73% to $39.8 million in 2026.
• Business Quant data shows XENE's Total Current Liabilities at $39.8 million in Q1 2026, $41.8 million in Q4 2025, and $38.3 million in Q3 2025.